secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-275910
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImageneBio reports Q3 net loss of $24.8M; advances Phase 2b AD trial with protocol amendment
--------------------------------------------------------------------------------

- Cash, equivalents, and marketable securities $142.6M as of Sep 30, 2025; net loss $24.8M for Q3 2025 vs $3.2M in Q3 2024; R&D $15.6M, G&A $11.0M.
- Phase 2b ADAPTIVE trial protocol amendment to expand dosing regimens; topline data expected in 2027; enrollment ongoing.
- New alopecia areata data (Phase 1b/2a) and atopic dermatitis data to be presented at ISDS Nov 12-15, 2025.
- Completed reverse merger with Ikena Oncology and $75M private placement; new CEO Kristin Yarema, CSO Kurinji Pandiyan, CTO Renuka Sivendran, and independent director Joe Slattery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312525275910/0001193125-25-275910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312525275910/d61077d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-275910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer